4.7 Article

Topical Delivery of Ketorolac Tromethamine via Cataplasm for Inflammatory Pain Therapy

期刊

PHARMACEUTICS
卷 15, 期 5, 页码 -

出版社

MDPI
DOI: 10.3390/pharmaceutics15051405

关键词

ketorolac tromethamine; topical drug delivery system; cataplasm; anti-inflammatory; analgesic

向作者/读者索取更多资源

Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used for treating inflammatory pain, including osteoarthritis. Ketorolac tromethamine, a strong NSAID with anti-inflammatory and analgesic properties, can cause adverse effects when administered orally or through injections. To address this issue, a topical delivery system in the form of a cataplasm was designed and fabricated, which showed comparable effectiveness in reducing inflammation and pain as oral administration. The cataplasm also demonstrated reduced side effects in human volunteers, making it a better alternative for the treatment of inflammatory pain.
Nonsteroidal anti-inflammatory drugs (NSAIDs) have been widely used in the treatment of inflammatory pain, such as in osteoarthritis. Ketorolac tromethamine is considered to be an NSAID with strong anti-inflammatory and analgesic potency, however, traditional applications, such as oral administration and injections, often induce high systemic exposure, leading to adverse events such as gastric ulceration and bleeding. To address this key limitation, herein we designed and fabricated a topical delivery system for ketorolac tromethamine via cataplasm, which is based on a three-dimensional mesh structure formed by the cross-linking of dihydroxyaluminum aminoacetate (DAAA) and sodium polyacrylate. The viscoelasticity of the cataplasm was characterized by rheological methods and exhibited a gel-like elastic property. The release behavior showed a Higuchi model characteristic with a dose dependence. To enhance the skin permeation, permeation enhancers were added and screened utilizing ex vivo pig skin, in which 1,2-propanediol was found to have the optimal permeation-promoting effect. The cataplasm was further applied to a rat carrageenan-induced inflammatory pain model, which showed comparable anti-inflammatory and analgesic effects with oral administration. Finally, the biosafety of the cataplasm was tested in healthy human volunteers, and reduced side effects were achieved as compared to the tablet formulation, which can be ascribed to less systemic drug exposure and lower blood drug concentrations. Therefore, the constructed cataplasm can reduce the risk of adverse events while maintaining efficacy, thus serving as a better alternative for the treatment of inflammatory pain, including osteoarthritis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据